Skip to main content

Table 1 Patient characteristics by body mass index (BMI, kg/m2) groups

From: Obesity and breast cancer outcomes in chemotherapy patients in New Zealand – a population-based cohort study

Characteristics Total BMI < 21 BMI 21-24 BMI 25-29 BMI 30-34 BMI 35+ Chi-square % Obese Trend
N % N % N % N % N % N % p-value (BMI 30+) p-value
Total 1049   81 7.7 250 23.8 349 33.3 225 21.4 144 13.7   35.2  
Adjuvant treatment
 Chemotherapy alone 338 32.2 28 8.3 78 23.1 116 34.3 77 22.8 39 11.5 0.6 34.3  
 Chemotherapy and hormonal therapy 711 67.8 53 7.5 172 24.2 233 32.8 148 20.8 105 14.8   35.6  
Age
 <40 132 12.6 16 12.1 34 25.8 34 25.8 30 22.7 18 13.6 0.4 36.4 0.7
 40-59 678 64.6 52 7.7 162 23.9 230 33.9 137 20.2 97 14.3   34.5  
 60+ 239 22.6 13 5.4 54 22.6 85 35.6 58 24.3 29 12.1   36.4  
Menopausal status
 Pre-menopause 474 45.2 44 9.3 129 27.2 150 31.6 93 19.6 58 12.2 0.06 31.9 0.13
 Peri-menopause 65 6.2 0 0.0 16 24.6 22 33.8 18 27.7 9 13.8   41.5  
 Post-menopause 506 48.2 37 7.3 105 20.8 176 34.8 113 22.3 75 14.8   37.2  
 Missing/unknown 4 0.4 0 0.0 0 0.0 1 25 1 25.0 2 50.0   75.0  
Year of diagnosis
 2000-2002 190 18.1 16 8.4 51 26.8 66 34.7 40 21.1 17 8.9 0.5 30.0 0.2
 2003-2005 213 20.3 17 8.0 52 24.4 64 30 47 22.1 33 15.5   37.6  
 2006-2008 230 21.9 16 7.0 61 26.5 72 31.3 55 23.9 26 11.3   35.2  
 2009-2011 218 20.8 17 7.8 40 18.3 77 35.3 48 22.0 36 16.5   38.5  
 2012-2014 198 18.9 15 7.6 46 23.2 70 35.4 35 17.7 32 16.2   33.8  
Ethnicity
 European 793 75.6 69 8.7 204 25.7 283 35.7 158 19.9 79 10.0 <0.0001 29.9  
 Maori 194 18.5 7 3.6 34 17.5 47 24.2 55 28.4 51 26.3   54.6  
 Pacific 32 3.1 0 0.0 4 12.5 6 18.8 8 25.0 14 43.8   68.8  
 Others 30 2.9 5 16.7 8 26.7 13 43.3 4 13.3 0 0.0   13.3  
Deprivation score (higher means greater deprivation)
 1-2 127 12.1 7 5.5 40 31.5 47 37 21 16.5 12 9.4 0.2 26.0 0.002
 3-4 119 11.3 14 11.8 31 26.1 37 31.1 18 15.1 19 16.0   31.1  
 5-6 245 23.4 18 7.3 62 25.3 84 34.3 52 21.2 29 11.8   33.1  
 7-8 285 27.2 20 7.0 67 23.5 91 31.9 62 21.8 45 15.8   37.5  
 9-10 272 25.9 22 8.1 49 18.0 90 33.1 72 26.5 39 14.3   40.8  
 Missing/unknown 1 0.1 0 0.0 1 100.0 0 0 0 0.0 0 0.0   0.0  
Area of residence
 Urban 614 58.5 52 8.5 143 23.3 197 32.1 131 21.3 91 14.8 0.2 36.2  
 Semi-urban or rural 406 38.7 29 7.1 94 23.2 144 35.5 89 21.9 50 12.3   34.2  
 Missing/unknown 29 2.8 0 0.0 13 44.8 8 27.6 5 17.2 3 10.3   27.6  
Comorbidity (C3 index score)
 0 912 86.9 75 8.2 226 24.8 312 34.2 187 20.5 112 12.3 0.05 32.8 <0.001
 1 75 7.1 4 5.3 13 17.3 20 26.7 21 28.0 17 22.7   50.7  
 2 40 3.8 1 2.5 7 17.5 11 27.5 11 27.5 10 25.0   52.5  
 3+ 22 2.1 1 4.5 4 18.2 6 27.3 6 27.3 5 22.7   50.0  
Screen-detected
 Yes 303 28.9 17 5.6 57 18.8 117 38.6 72 23.8 40 13.2 0.02 37.0  
 No 746 71.1 64 8.6 193 25.9 232 31.1 153 20.5 104 13.9   34.5  
Stage at diagnosis
 I 147 14 15 10.2 38 25.9 47 32 28 19.0 19 12.9 0.5 32.0 0.06
 II 537 51.2 34 6.3 137 25.5 186 34.6 114 21.2 66 12.3   33.5  
 III 309 29.5 25 8.1 67 21.7 97 31.4 70 22.7 50 16.2   38.8  
 IV 56 5.3 7 12.5 8 14.3 19 33.9 13 23.2 9 16.1   39.3  
Grade
 I 83 7.9 7 8.4 27 32.5 27 32.5 14 16.9 8 9.6 0.6 26.5 0.7
 II 512 48.8 35 6.8 120 23.4 167 32.6 113 22.1 77 15.0   37.1  
 III 425 40.5 36 8.5 100 23.5 145 34.1 89 20.9 55 12.9   33.9  
 Missing/unknown 29 2.8 3 10.3 3 10.3 10 34.5 9 31.0 4 13.8   44.8  
Histology
 Ductal 898 85.6 71 7.9 214 23.8 295 32.9 188 20.9 130 14.5 0.5 35.4  
 Lobular 94 9 8 8.5 21 22.3 30 31.9 25 26.6 10 10.6   37.2  
 Other 57 5.4 2 3.5 15 26.3 24 42.1 12 21.1 4 7.0   28.1  
ER/PR
 ER+/PR+ 515 49.1 37 7.2 124 24.1 166 32.2 115 22.3 73 14.2 0.9 36.5  
 ER+/PR- 216 20.6 20 9.3 49 22.7 75 34.7 38 17.6 34 15.7   33.3  
 ER-/PR+ 22 2.1 2 9.1 5 22.7 6 27.3 5 22.7 4 18.2   40.9  
 ER-/PR- 270 25.7 20 7.4 64 23.7 92 34.1 62 23.0 32 11.9   34.8  
 Missing/unknown 26 2.5 2 7.7 8 30.8 10 38.5 5 19.2 1 3.8   23.1  
HER-2
 Positive 274 26.1 20 7.3 60 21.9 90 32.8 57 20.8 47 17.2 0.7 38.0  
 Equivocal 27 2.6 1 3.7 7 25.9 7 25.9 8 29.6 4 14.8   44.4  
 Negative 554 52.8 47 8.5 128 23.1 189 34.1 119 21.5 71 12.8   34.3  
 Missing/unknown 194 18.5 13 6.7 55 28.4 63 32.5 41 21.1 22 11.3   32.5  
Primary treatment (RT = radiotherapy)
 Breast conserving surgery with RT 451 43 29 6.4 99 22.0 152 33.7 111 24.6 60 13.3 0.1 37.9  
 Breast conserving surgery, no RT 45 4.3 3 6.7 17 37.8 15 33.3 6 13.3 4 8.9   22.2  
 Mastectomy with RT 379 36.1 33 8.7 93 24.5 124 32.7 69 18.2 60 15.8   34.0  
 Mastectomy, no RT 130 12.4 11 8.5 35 26.9 47 36.2 24 18.5 13 10.0   28.5  
 No primary surgery 44 4.2 5 11.4 6 13.6 11 25 15 34.1 7 15.9   50.0  
Total breast conserving surgery 496 47.3 32 13.1 116 59.7 167 67.0 117 37.9 64 22.2 0.3 36.5  
 Total mastectomy 509 48.5 44 17.2 128 51.5 171 68.9 93 36.7 73 25.8   32.6  
 Total with RT 830 79.1 62 15.1 192 46.5 276 66.4 180 42.8 120 29.1 0.02 36.1  
 Total without RT 175 16.7 14 15.1 52 64.7 62 69.5 30 31.8 17 18.9   26.9  
Facility where primary treatment was undertaken
 Private 377 35.9 34 9.0 112 29.7 141 37.4 54 14.3 36 9.5 <0.0001 23.9  
 Public 672 64.1 47 7.0 138 20.5 208 31.0 171 25.4 108 16.1   41.5  
  1. Chi-sq P value based on table for each factor. Trend P value based on trend in proportion obese over ordered categories of factor